Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.

Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, Eder JP, Jones RL, Lu H, Ter Meulen JH, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SM.

Clin Cancer Res. 2019 Jun 21. doi: 10.1158/1078-0432.CCR-19-1025. [Epub ahead of print]

PMID:
31227504
2.

Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.

Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SM.

Cancer Immunol Res. 2019 Aug;7(8):1237-1243. doi: 10.1158/2326-6066.CIR-18-0940. Epub 2019 Jun 6.

PMID:
31171504
3.

MRI Radiomic Features Are Independently Associated With Overall Survival in Soft Tissue Sarcoma.

Spraker MB, Wootton LS, Hippe DS, Ball KC, Peeken JC, Macomber MW, Chapman TR, Hoff MN, Kim EY, Pollack SM, Combs SE, Nyflot MJ.

Adv Radiat Oncol. 2019 Feb 23;4(2):413-421. doi: 10.1016/j.adro.2019.02.003. eCollection 2019 Apr-Jun.

4.

Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer.

Seo YD, Jiang X, Sullivan KM, Jalikis FG, Smythe KS, Abbasi A, Vignali M, Park JO, Daniel SK, Pollack SM, Kim TS, Yeung R, Crispe IN, Pierce RH, Robins H, Pillarisetty VG.

Clin Cancer Res. 2019 Jul 1;25(13):3934-3945. doi: 10.1158/1078-0432.CCR-19-0081. Epub 2019 Apr 2.

PMID:
30940657
5.

Monthly Versus Treat-and-Extend Ranibizumab for Diabetic Macular Edema: A Prospective, Randomized Trial.

Eichenbaum DA, Duerr E, Patel HR, Pollack SM.

Ophthalmic Surg Lasers Imaging Retina. 2018 Nov 1;49(11):e191-e197. doi: 10.3928/23258160-20181101-17.

PMID:
30457655
6.

Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review.

Riedel RF, Jones RL, Italiano A, Bohac C, Thompson JC, Mueller K, Khan Z, Pollack SM, Van Tine BA.

Cancers (Basel). 2018 Nov 1;10(11). pii: E417. doi: 10.3390/cancers10110417. Review.

7.

Response to PD1 inhibition in conventional chondrosarcoma.

Wagner MJ, Ricciotti RW, Mantilla J, Loggers ET, Pollack SM, Cranmer LD.

J Immunother Cancer. 2018 Sep 25;6(1):94. doi: 10.1186/s40425-018-0413-z.

8.

Propranolol for the treatment of vascular sarcomas.

Wagner MJ, Cranmer LD, Loggers ET, Pollack SM.

J Exp Pharmacol. 2018 Sep 6;10:51-58. doi: 10.2147/JEP.S146211. eCollection 2018. Review.

9.

More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven Treatments.

Katz D, Palmerini E, Pollack SM.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:925-938. doi: 10.1200/EDBK_205423. Review.

PMID:
30231352
10.

Limited activity of metronomic cyclophosphamide and pembrolizumab for soft tissue sarcomas.

Lien IC, Pollack SM.

Transl Gastroenterol Hepatol. 2018 Jan 15;3:4. doi: 10.21037/tgh.2017.12.09. eCollection 2018. No abstract available.

11.

Advances in the treatment of soft tissue sarcoma: focus on eribulin.

Koliou P, Karavasilis V, Theochari M, Pollack SM, Jones RL, Thway K.

Cancer Manag Res. 2018 Feb 1;10:207-216. doi: 10.2147/CMAR.S143019. eCollection 2018. Review.

12.

The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.

Pollack SM.

Expert Rev Vaccines. 2018 Feb;17(2):107-114. doi: 10.1080/14760584.2018.1419068. Epub 2017 Dec 27. Review.

13.

Emerging Targeted and Immune-Based Therapies in Sarcoma.

Pollack SM, Ingham M, Spraker MB, Schwartz GK.

J Clin Oncol. 2018 Jan 10;36(2):125-135. doi: 10.1200/JCO.2017.75.1610. Epub 2017 Dec 8. Review.

PMID:
29220291
14.

Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas.

Pierce DB, Johnson GE, Monroe E, Loggers ET, Jones RL, Pollack SM, Padia SA.

AJR Am J Roentgenol. 2018 Jan;210(1):175-182. doi: 10.2214/AJR.16.17573. Epub 2017 Nov 1.

PMID:
29090997
15.

First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient.

Pollack SM, Lu H, Gnjatic S, Somaiah N, O'Malley RB, Jones RL, Hsu FJ, Ter Meulen J.

J Immunother. 2017 Oct;40(8):302-306. doi: 10.1097/CJI.0000000000000183.

16.

Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma.

Jones RL, Katz D, Loggers ET, Davidson D, Rodler ET, Pollack SM.

Med Oncol. 2017 Aug 29;34(10):167. doi: 10.1007/s12032-017-1030-2.

17.

T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.

Pollack SM, He Q, Yearley JH, Emerson R, Vignali M, Zhang Y, Redman MW, Baker KK, Cooper S, Donahue B, Loggers ET, Cranmer LD, Spraker MB, Seo YD, Pillarisetty VG, Ricciotti RW, Hoch BL, McClanahan TK, Murphy E, Blumenschein WM, Townson SM, Benzeno S, Riddell SR, Jones RL.

Cancer. 2017 Sep 1;123(17):3291-3304. doi: 10.1002/cncr.30726. Epub 2017 May 2.

18.

Phase III Soft Tissue Sarcoma Trials: Success or Failure?

Lee AT, Pollack SM, Huang P, Jones RL.

Curr Treat Options Oncol. 2017 Mar;18(3):19. doi: 10.1007/s11864-017-0457-1. Review.

19.

The Imaging and Pathological Features of Metastatic Leiomyosarcoma in the Gallbladder.

Guo Y, Chen E, Davidson DJ, Pillarisetty VG, Jones RL, Pollack SM.

Rare Tumors. 2016 Dec 23;8(4):6618. doi: 10.4081/rt.2016.6618. eCollection 2016 Nov 17.

20.

Treatment of refractory gastrointestinal stromal tumor using pazopanib.

Lien IC, Pollack SM.

Transl Gastroenterol Hepatol. 2016 Nov 29;1:86. doi: 10.21037/tgh.2016.11.01. eCollection 2016. No abstract available.

21.

Novel therapeutic approaches in chondrosarcoma.

Polychronidou G, Karavasilis V, Pollack SM, Huang PH, Lee A, Jones RL.

Future Oncol. 2017 Mar;13(7):637-648. doi: 10.2217/fon-2016-0226. Epub 2017 Jan 30. Review.

22.

Pazopanib in the management of advanced soft tissue sarcomas.

Cranmer LD, Loggers ET, Pollack SM.

Ther Clin Risk Manag. 2016 Jun 9;12:941-55. doi: 10.2147/TCRM.S84792. eCollection 2016. Review.

23.

Targeting gastrointestinal stromal tumors: the role of regorafenib.

Schroeder B, Li Z, Cranmer LD, Jones RL, Pollack SM.

Onco Targets Ther. 2016 May 20;9:3009-16. doi: 10.2147/OTT.S104081. eCollection 2016. Review.

24.

Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away.

Lee A, Huang P, DeMatteo RP, Pollack SM.

Am Soc Clin Oncol Educ Book. 2016;35:281-90. doi: 10.14694/EDBK_157439.

25.

Drug repositioning in sarcomas and other rare tumors.

Lee ATJ, Huang PH, Pollack SM, Jones RL.

EBioMedicine. 2016 Apr;6:4-5. doi: 10.1016/j.ebiom.2016.03.021. Epub 2016 Mar 17. No abstract available.

26.

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.

Palmerini E, Jones RL, Marchesi E, Paioli A, Cesari M, Longhi A, Meazza C, Coccoli L, Fagioli F, Asaftei S, Grignani G, Tamburini A, Pollack SM, Picci P, Ferrari S.

BMC Cancer. 2016 Apr 20;16:280. doi: 10.1186/s12885-016-2312-3.

27.

Trabectedin in soft tissue sarcomas.

Petek BJ, Loggers ET, Pollack SM, Jones RL.

Mar Drugs. 2015 Feb 12;13(2):974-83. doi: 10.3390/md13020974. Review.

28.

Recruiting U.S. and Canadian college students via social media for participation in a web-based brief intervention study.

Fazzino TL, Rose GL, Pollack SM, Helzer JE.

J Stud Alcohol Drugs. 2015 Jan;76(1):127-32.

29.

Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.

Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU 3rd, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C.

J Immunother Cancer. 2014 Oct 14;2(1):36. doi: 10.1186/s40425-014-0036-y. eCollection 2014.

30.

Analysis of clinical prognostic factors for adult patients with head and neck sarcomas.

Chang AE, Chai X, Pollack SM, Loggers E, Rodler E, Dillon J, Parvathaneni U, Moe KS, Futran N, Jones RL.

Otolaryngol Head Neck Surg. 2014 Dec;151(6):976-83. doi: 10.1177/0194599814551539. Epub 2014 Sep 25.

PMID:
25257906
31.

Management and outcome of metastatic clear cell sarcoma.

Constantinidou A, Pollack SM, Jones RL.

Eur J Surg Oncol. 2014 Oct;40(10):1383. doi: 10.1016/j.ejso.2014.05.015. Epub 2014 Aug 7. No abstract available.

PMID:
25138036
32.

Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.

Jour G, Scarborough JD, Jones RL, Loggers E, Pollack SM, Pritchard CC, Hoch BL.

Hum Pathol. 2014 Aug;45(8):1563-71. doi: 10.1016/j.humpath.2014.04.012. Epub 2014 Apr 24.

PMID:
24908143
33.

Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.

Shibuya KC, Goel VK, Xiong W, Sham JG, Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR, Pillarisetty VG.

PLoS One. 2014 May 2;9(5):e96565. doi: 10.1371/journal.pone.0096565. eCollection 2014.

34.

The multidisciplinary management of giant cell tumor of bone.

Ng VY, Davidson DJ, Kim EY, Pollack SM, Conrad Iii EU, Jones RL.

Expert Rev Anticancer Ther. 2014 Jul;14(7):783-90. doi: 10.1586/14737140.2014.901891. Epub 2014 Mar 26. Review.

PMID:
24666240
35.

A contemporary large single-institution evaluation of resected retroperitoneal sarcoma.

Bremjit PJ, Jones RL, Chai X, Kane G, Rodler ET, Loggers ET, Pollack SM, Pillarisetty VG, Mann GN.

Ann Surg Oncol. 2014 Jul;21(7):2150-8. doi: 10.1245/s10434-014-3616-7. Epub 2014 Mar 11.

PMID:
24615180
36.

Systemic therapy in advanced uterine adenosarcoma with sarcomatous overgrowth.

Schroeder B, Pollack SM, Jones RL.

Gynecol Oncol. 2014 Feb;132(2):513. doi: 10.1016/j.ygyno.2013.09.035. Epub 2013 Dec 11. No abstract available.

PMID:
24333501
37.

Multiple liver abscess formation and primary gastrointestinal stromal tumor.

Chang AE, Mann GN, Hoch B, Loggers ET, Pollack SM, Kolokythas O, Jones RL.

Rare Tumors. 2013 Sep 4;5(3):e51. doi: 10.4081/rt.2013.e51. eCollection 2013.

38.

Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants.

Bathan AJ, Constantinidou A, Pollack SM, Jones RL.

Curr Opin Oncol. 2013 Jul;25(4):384-9. doi: 10.1097/CCO.0b013e3283622c77. Review.

PMID:
23635801
39.

The use of radiofrequency ablation in gastrointestinal stromal tumor.

Pollack SM, Pillarisetty VG, Padia SA, Jones RL.

J Vasc Interv Radiol. 2013 May;24(5):751. doi: 10.1016/j.jvir.2013.02.026. No abstract available.

PMID:
23622046
40.

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib.

Rajendra R, Jones RL, Pollack SM.

Onco Targets Ther. 2013;6:217-22. doi: 10.2147/OTT.S32200. Epub 2013 Mar 18.

41.

Clinical benefit of trabectedin in uterine adenosarcoma.

Schroeder BA, Rodler ET, Loggers ET, Pollack SM, Jones RL.

Med Oncol. 2013 Jun;30(2):501. doi: 10.1007/s12032-013-0501-3. Epub 2013 Feb 28.

PMID:
23456619
42.

Management of gastrointestinal stromal tumors.

Rajendra R, Pollack SM, Jones RL.

Future Oncol. 2013 Feb;9(2):193-206. doi: 10.2217/fon.12.178. Review.

PMID:
23414470
43.

Systemic therapy in primary angiosarcoma of the spleen.

Ferreira BP, Rodler ET, Loggers ET, Pollack SM, Jones RL.

Rare Tumors. 2012 Oct 10;4(4):e55. doi: 10.4081/rt.2012.e55. Epub 2012 Nov 13.

44.

MDM2 inhibition in liposarcoma: a step in the right direction.

Constantinidou A, Pollack SM, Jones RL.

Lancet Oncol. 2012 Nov;13(11):1070-1. doi: 10.1016/S1470-2045(12)70457-6. Epub 2012 Oct 17. No abstract available.

PMID:
23084518
45.

The road less traveled.

Pollack SM.

N Engl J Med. 2012 Mar 15;366(11):1061; author reply 1062. doi: 10.1056/NEJMc1201041. No abstract available.

PMID:
22417269
46.

NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.

Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU 3rd, Jones RL, Yee C.

PLoS One. 2012;7(2):e32165. doi: 10.1371/journal.pone.0032165. Epub 2012 Feb 27.

47.

NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.

Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU 3rd, Jones RL, Yee C.

Cancer. 2012 Sep 15;118(18):4564-70. doi: 10.1002/cncr.27446. Epub 2012 Feb 22.

48.

Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.

Chou J, Voong LN, Mortales CL, Towlerton AM, Pollack SM, Chen X, Yee C, Robbins PF, Warren EH.

J Immunother. 2012 Feb-Mar;35(2):131-41. doi: 10.1097/CJI.0b013e31824300c7.

49.

Immune-based therapies for sarcoma.

Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RL.

Sarcoma. 2011;2011:438940. doi: 10.1155/2011/438940. Epub 2011 Jan 23.

50.

Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.

Bishop MR, Dean RM, Steinberg SM, Odom J, Pollack SM, Pavletic SZ, Sportes C, Gress RE, Fowler DH.

Cancer. 2010 Feb 15;116(4):852-62. doi: 10.1002/cncr.24845.

Supplemental Content

Loading ...
Support Center